Taking Steps to Manage Adverse Events Associated with Checkpoint Inhibitors
November 29th 2016The observed adverse events that have been associated with immunotherapy, especially immunotherapy combinations, have to be properly assessed against their clearly improved efficacy in patients with otherwise dismal prognosis from stage IV cancers.
Read More